share_log

HC Wainwright & Co. Reiterates Buy on Surface Oncology, Maintains $6 Price Target

HC Wainwright & Co. Reiterates Buy on Surface Oncology, Maintains $6 Price Target

HC Wainwright & Co.重申买入 Surface Oncology,维持6美元的目标价格
Benzinga ·  2023/03/10 06:58

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Surface Oncology (NASDAQ:SURF) with a Buy and maintains $6 price target.

HC Wainwright&Co.分析师Swayampakula Ramakanth重申表面肿瘤学(纳斯达克:SURF)的买入,并维持6美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发